Skip to main content
Premium Trial:

Request an Annual Quote

Skuldtech Receives $1.3M for Alzheimer's Dx Development

NEW YORK (GenomeWeb News) – French biomarker firm Skuldtech today announced it has been awarded €1 million ($1.3 million) in funding to support work on developing diagnostic tests for an Alzheimer's drug in development.

The funding is from Bpifrance, a French public financing structure, and is part of a project on Alzheimer's that has received €8.6 million in total funding. The program, Skuldtech said, is anticipated to last four years with the first results expected in 2018.

The funding to Skuldtech will go toward the use of the company's broadband sequencing-based technology platform, paired with proprietary bioinformatics and biostatistics programs, to measure and confirm the progression of Alzheimer's disease. Skuldtech plans to develop a companion diagnostic for AB Science's masitinib molecule, which is in a Phase III trial.

It also will develop a diagnostic for predicting Alzheimer's progression.

Skuldtech will use blood samples from the masitinib trial to identify biomarkers with diagnostic applications with the aim of developing tests that can be used to tailor treatments for patients and to monitor them as their disease progresses. The masitinib clinical trial was launched in May and is expected to include 400 patients.

Skuldtech said that it was successful in using the same approach to develop a treatment for pancreatic cancer that combined gemcitabine with masitinib. In that case, the company identified new biomarkers that predicted favorable response to the treatment.

"This new partnership to work on Alzheimer's disease will strengthen Skuldtech's position in the field of personalized medicine and in the development of companion diagnostics associated with new treatments in phases of clinical trials," Skuldtech CEO Didier Ritter said in a statement.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.